Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Calcium channel blocker use and risk of Parkinson's disease.

Literature DB >> 20669249

Calcium channel blocker use and risk of Parkinson's disease.

Kelly Claire Simon¹, Xiang Gao, Honglei Chen, Michael A Schwarzschild, Alberto Ascherio.

Abstract

We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.

Entities: Chemical Disease Species

Mesh：

Substances：
Calcium Channel Blockers

Year: 2010 PMID： 20669249 PMCID： PMC2939261 DOI： 10.1002/mds.23191

Source DB: PubMed Journal: Mov Disord ISSN： 0885-3185 Impact factor: 10.338

11 in total

1. The action of MPTP on synaptic transmission is affected by changes in Ca2+ concentrations.

Authors: J A Wilson; Y S Lau; J G Gleeson; J S Wilson
Journal: Brain Res Date: 1991-02-15 Impact factor: 3.252

2. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease.

Authors: C Savio Chan; Jaime N Guzman; Ema Ilijic; Jeff N Mercer; Caroline Rick; Tatiana Tkatch; Gloria E Meredith; D James Surmeier
Journal: Nature Date: 2007-06-10 Impact factor: 49.962

Review 3. Calcium, ageing, and neuronal vulnerability in Parkinson's disease.

Authors: D James Surmeier
Journal: Lancet Neurol Date: 2007-10 Impact factor: 44.182

4. Use of antihypertensives and the risk of Parkinson disease.

Authors: Alberto Ascherio; Caroline M Tanner
Journal: Neurology Date: 2009-02-10 Impact factor: 9.910

5. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease.

Authors: J P Sheehan; R H Swerdlow; W D Parker; S W Miller; R E Davis; J B Tuttle
Journal: J Neurochem Date: 1997-03 Impact factor: 5.372

Review 6. Neuronal vulnerability in Parkinson's disease.

Authors: E C Hirsch; B Faucheux; P Damier; A Mouatt-Prigent; Y Agid
Journal: J Neural Transm Suppl Date: 1997

7. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

Authors: A Ascherio; S M Zhang; M A Hernán; I Kawachi; G A Colditz; F E Speizer; W C Willett
Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422

Review 8. Calcium and neurodegeneration.

Authors: Mark P Mattson
Journal: Aging Cell Date: 2007-02-28 Impact factor: 9.304

9. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease.

Authors: G Forte; B Bocca; O Senofonte; F Petrucci; L Brusa; P Stanzione; S Zannino; N Violante; A Alimonti; G Sancesario
Journal: J Neural Transm (Vienna) Date: 2004-03-19 Impact factor: 3.575

10. Use of antihypertensives and the risk of Parkinson disease.

Authors: Claudia Becker; Susan S Jick; Christoph R Meier
Journal: Neurology Date: 2008-02-06 Impact factor: 9.910

16 in total

1. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.

Authors: E Ilijic; J N Guzman; D J Surmeier
Journal: Neurobiol Dis Date: 2011-04-16 Impact factor: 5.996

2. A Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain Protein Expression in Wild Type and Transgenic APPSweDI Mice.

Authors: Baiba Jansone; Inga Kadish; Thomas van Groen; Ulrika Beitnere; Doyle Ray Moore; Aiva Plotniece; Karlis Pajuste; Vija Klusa
Journal: PLoS One Date: 2015-06-04 Impact factor: 3.240

3. Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice.

Authors: Adebimpe W Kasumu; Xia Liang; Polina Egorova; Daria Vorontsova; Ilya Bezprozvanny
Journal: J Neurosci Date: 2012-09-12 Impact factor: 6.167

Review 4. Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.

Authors: Tara Swart; Michael J Hurley
Journal: CNS Drugs Date: 2016-12 Impact factor: 5.749

Review 5. Physiological phenotype and vulnerability in Parkinson's disease.

Authors: D James Surmeier; Jaime N Guzman; Javier Sanchez; Paul T Schumacker
Journal: Cold Spring Harb Perspect Med Date: 2012-07 Impact factor: 6.915

6. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2.

Authors: Adebimpe W Kasumu; Charlotte Hougaard; Frederik Rode; Thomas A Jacobsen; Jean Marc Sabatier; Birgitte L Eriksen; Dorte Strøbæk; Xia Liang; Polina Egorova; Dasha Vorontsova; Palle Christophersen; Lars Christian B Rønn; Ilya Bezprozvanny
Journal: Chem Biol Date: 2012-10-26